Karol Rosner, MD
Nephrology · Hannibal, MONPI 1053425884
Payments from drug & device makers
Across 61 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$164
- Travere Therapeutics, Inc.$158
- Calliditas Therapeutics US Inc.$137
- Novartis$121
- Bayer$116
- Vifor Pharma, Inc.$83
- plus $483 from 12 others
What the payments were for
- Food & beverage$1,24398%
- Education$202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $164 |
| Travere Therapeutics, Inc. | 11 | $158 |
| Calliditas Therapeutics US Inc. | 3 | $137 |
| Novartis | 6 | $121 |
| Bayer | 6 | $116 |
| Vifor Pharma, Inc. | 4 | $83 |
| Biotronik Inc. | 1 | $82 |
| Otsuka America Pharmaceutical, Inc. | 4 | $76 |
| Fresenius USA Marketing, Inc. | 3 | $62 |
| Scpharmaceuticals Inc. | 3 | $53 |
| AstraZeneca | 3 | $51 |
| Biomerieux Inc | 2 | $33 |
| Ardelyx, Inc. | 2 | $31 |
| Apellis Pharmaceuticals, Inc. | 1 | $25 |
| Akebia Therapeutics Inc | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| GSK | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$100
How this compares
$1,263 in reported general payments places this provider in the 55th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Paricalcitol | 50 | $5,035 |
| Sevelamer Carbonate | 12 | $4,845 |
| Bumetanide | 37 | $1,432 |
| Potassium Chloride | 25 | $642 |
| Spironolactone | 34 | $409 |
| Lisinopril | 44 | $301 |
| Losartan Potassium | 22 | $248 |
| Amlodipine Besylate | 25 | $220 |
| Metoprolol Succinate | 13 | $207 |
| Tamsulosin Hcl | 21 | $165 |
| Hydralazine Hcl | 18 | $126 |
| Furosemide | 39 | $125 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Hannibal
- Ahmed AwadKansas City$12.4M
- Benjamin HumphreysSaint Louis$1.2M
- Donovan PolackFlorissant$782K
- Derek LarsonCreve Coeur$605K
- Gary SingerSaint Peters$580K
- Daniel CoyneSaint Louis$563K
- Tarek AlhamadSaint Louis$477K
- Tingting LiSaint Louis$370K
- Anuja JavaSaint Louis$365K
- Marcos RothsteinSaint Louis$350K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.